Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,200.00
Bid: 12,198.00
Ask: 12,200.00
Change: 104.00 (0.86%)
Spread: 2.00 (0.016%)
Open: 12,150.00
High: 12,286.00
Low: 12,134.00
Prev. Close: 12,096.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 10-Britain reports first death with Omicron coronavirus variant

Mon, 13th Dec 2021 07:20

* First publicly confirmed death globally from Omicron

* 200,000 Omicron infections per day in UK -health minister

* Get a booster as two vaccines not enough, Britain says

* Omicron will be dominant variant in London in 48 hours
(Adds more detail from health secretary)

By Guy Faulconbridge and Michael Holden

LONDON, Dec 13 (Reuters) - At least one person has died in
the United Kingdom after contracting the Omicron coronavirus
variant, Prime Minister Boris Johnson said on Monday, the first
publicly confirmed death globally from the swiftly spreading
strain.

Since the first Omicron cases were detected on Nov. 27 in
Britain, Johnson has imposed tougher restrictions and on Sunday
cautioned that the variant could overcome the immune defences of
those inoculated with two shots of vaccines.

Britain gave no details on the death other than the person
had been diagnosed in hospital. It was not clear if the patient
had been vaccinated or had underlying health issues.

Deaths from Omicron may have occurred in other countries but
none has been publicly confirmed yet outside Britain.

"Sadly at least one patient has now been confirmed to have
died with Omicron," Johnson told reporters at a vaccination
centre in London.

"So I think the idea that this is somehow a milder version
of the virus - I think that's something we need to set (to) one
side - and just recognise the sheer pace at which it accelerates
through the population."

Health Secretary Sajid Javid said the variant now accounted
for 44% of infections in London and would be the dominant strain
in the capital within 48 hours. New Omicron infections are
estimated at 200,000 per day, Javid said.

Before the death was announced, Britain said 10 people had
been hospitalised with Omicron in various parts of England.
Their ages ranged from 18 to 85 years and most had received two
vaccination doses.

The UK Health Security Agency said Omicron - first detected
in South Africa, Botswana and Hong Kong in late November - can
overcome the immunity of those who have had two shots of
vaccines such as AstraZeneca or Pfizer-BioNTech
.

South Africa's health ministry said it was unable to say
with certainty if any of its COVID-19 deaths were caused by
Omicron as deaths were not broken down by variant.

The World Health Organization said on Sunday that while
preliminary findings from South Africa suggest Omicron may be
less severe than the Delta variant - currently dominant
worldwide, and all cases reported in the Europe region have been
mild or asymptomatic, it remains unclear to what extent Omicron
may be inherently less virulent.

NEW LOCKDOWNS?

Johnson, now grappling with a rebellion in his party over
measures to curb Omicron and an outcry over staff parties at his
Downing Street office during last year's lockdowns, said people
should rush to get booster vaccines to protect "our freedoms and
our way of life".

After COVID-19 was first detected in China in late 2019, he
faced criticism for initially resisting lockdown.

He has also been criticised for overseeing mistakes in
transferring patients into care homes, and for building a costly
test-and-trace system that failed to stop a deadly second wave.

Johnson has repeatedly said that while mistakes were made,
the government was making decisions swiftly in the biggest
public health crisis for generations and that it was quick to
roll out vaccines.

More than 146,000 people have died from COVID-19 in the
United Kingdom.

Asked if he could rule out tougher restrictions in England
before Christmas, Johnson avoided giving a direct answer. His
health minister, Javid, said he knew of no plans for additional
measures. "There are no plans that I am aware of for any further
restrictions," Javid said.

VACCINE QUEUES

Johnson faces growing anger from libertarians in his party
over tougher curbs on daily life and sinking poll ratings.

He has also faced criticism over his handling of a sleaze
scandal, the awarding of lucrative COVID contracts, the
refurbishment of his Downing Street flat, and a claim that he
intervened to ensure pets were evacuated from Kabul during the
chaotic Western withdrawal from Afghanistan in August.

An Ipsos MORI poll for The London Evening Standard newspaper
showed opposition Labour leader Keir Starmer's ranking was 13
percentage points ahead of Johnson, the first time a Labour
chief was viewed as a more capable prime minister since 2008.

It also echoed other polls by showing Labour up three points
on 39% ahead of Johnson's Conservatives, who were down one point
since the last survey in November on 35%.

At St. Thomas' Hospital Vaccination Centre in central
London, a queue of hundreds of people snaked back onto
Westminster Bridge. Reuters journalists also documented queues
across London and in Manchester, northern England.

"The COVID vaccine booking service is currently facing
extremely high demand so is operating a queuing system," the
National Health Service said on Twitter. It suggested trying
again later.

Home testing kits were also unavailable to order.
(Reporting by Guy Faulconbridge and Michael Holden and Hannah
McKay; Editing by Angus MacSwan, Giles Elgood and Mark Heinrich)

More News
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.